In addition, TXNDC5 may be a predictive marker for histone deacetylase inhibitor (HDACI) resistance in cutaneous T-cell lymphoma during drug treatment of the disease (159), a predictive marker for resistance to bortezomib in refractory/relapsed multiple myeloma (160), a regulatory target of simvastatin to enhance docetaxel-induced cytotoxicity in human prostate cancer cells (161) and may be a key factor in the antioxidant effect of statins. This evidence concerns the gene TXNDC5 and prostate cancer.